DALE NELSON: Open Payments
NPI 1376856385 · PUYALLUP, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,807 in 101 payments from 21 companies in 2025. Trend: 2023 $1,239 · 2024 $2,177 · 2025 $1,807
Food & beverage: $1,807
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 16 | $344 |
| ABBVIE INC. | 25 | $269 |
| PFIZER INC. | 15 | $207 |
| Corcept Therapeutics | 8 | $199 |
| AstraZeneca Pharmaceuticals LP | 7 | $150 |
| GlaxoSmithKline, LLC. | 5 | $113 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $95 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $76 |
| Lilly USA, LLC | 3 | $73 |
| Collegium Pharmaceutical, Inc. | 3 | $53 |
Products named: Ozempic, Korlym, PREVNAR 20, SHINGRIX, VRAYLAR, CAPLYTA, UBRELVY, QULIPTA.
Industry payments across WA — which companies pay providers there.
